Modeling Myelin Disruption and Repair for Therapeutic Assessment

Demyelinating diseases present persistent challenges for therapeutic development.

Species differences in oligodendrocyte development, limited persistence of myelinating populations in vitro, and the absence of functional readouts have contributed to low translational success rates. Human-derived neural organoids containing central and peripheral myelinating cell types offer a controlled framework for studying myelin development, disruption, and repair with greater biological fidelity.

Join us for a webinar on December 17, 2025, where we will showcase how CNS-3D and PNS-3D organoids can reproduce structural, molecular, and functional aspects of myelin biology, offering a more informative foundation for mechanistic research and early-stage evaluation of therapeutic candidates in demyelinating disease.

‍

Discussion Points

‍

CNS-3D maturation follows temporal patterns consistent with human neurodevelopment, with oligodendrocyte markers such as SOX10 and myelin basic protein (MBP) emerging later than neuronal and astrocytic markers.

Clemastine produces dose- and time-dependent increases in MBP expression at both the transcript and protein levels, supporting the suitability of the system for evaluating promyelinating compounds.

Peripheral nerve organoids illustrate the necessity of Schwann cells for functional myelination, with electron microscopy confirming compact myelin only in Schwann cell–containing cultures.

‍

Speaker

‍
Andrew LaCroix, PhD
Lead Scientist, 28bio

‍
Andrew LaCroix is a Lead Scientist at 28bio specializing in the development of iPSC-derived brain organoid models and their applications to preclinical safety and efficacy testing. Specifically, he has focused on predictive neurotoxicity assays and human-first drug discovery to reduce clinical failure rates and improve patient outcomes.

Register Today

‍